Phase 2 trial of bezisterim in newly diagnosed patients to start soon

The term 'clinical trials' is shown with a handful of oral medications above it and a heart rate graph below it.

The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients is scheduled to begin in early 2025.

BioVie, the therapy’s developer, has secured over $15 million to cover complete costs of the trial, and top-line findings are expected to be available before next year’s close, according to a company press release.

In Parkinson’s, neuroinflammation — an inflammatory response in the brain — is believed to play a key role in the damage and degeneration of dopamine-producing nerve cells, which are gradually lost in the disease. Dopamine is a crucial neurotransmitter that enables communication between nerve cells and helps to regulate movement, among other functions.

Recommended Reading

A woman is shown walking with assistance.

Side-to-side eye movement can improve stability in Parkinson’s

Bezisterim aims to lower neuroinflammation and improve insulin sensitivity

Many patients also show brain insulin resistance, a condition wherein brain cells become less responsive to insulin, impairing their ability to use blood sugar for energy production. This disruption in cellular energy metabolism is thought to contribute to the neurological symptoms of Parkinson’s.

Bezisterim, formerly known as NE3107, is a small molecule designed to enter the brain and enhance its anti-inflammatory responses while improving insulin sensitivity. The compound was originally developed by NeurMedix, and in 2021 BioVie acquired the rights to the drug.

A previous Phase 2a trial (NCT05083260) evaluated bezisterim in 46 adults with moderate to severe Parkinson’s disease, ages 30 to 80. The therapy was administered twice daily as an oral capsule, alongside a standard carbidopa/levodopa regimen, and compared with a placebo.

After about one month of treatment, results indicated that bezisterim was associated with a greater reduction in disease motor symptoms than with the placebo, especially in patients who were younger than age 70.

Additionally, bezisterim-treated patients experienced a more noticeable reduction in nonmotor Parkinson’s symptoms, such as sleep difficulties and restless leg syndrome.

Phase 2 trial to enroll up to 60 people newly diagnosed with Parkinson’s

The SUNRISE-PD clinical trial, a multicenter study, aims to evaluate the safety and effectiveness of bezisterim as a first-line treatment for newly diagnosed Parkinson’s patients not yet using carbidopa/levodopa therapy.

Up to 60 people will be randomly assigned to either 20 mg of bezisterim or a placebo, taken twice daily, for approximately three months.

They will have the option to participate either from their home or at a clinical site. For those choosing at-home participation, nurses will visit regularly to conduct study assessments, while a neurologist will provide remote consultations via video. All collected data will be reviewed and scored later by a central rating committee.

A new, once-daily formulation of bezisterim also will be evaluated in a planned Phase 3 trial in people with Alzheimer’s disease, with trial initiation expected in late 2025.

The post Phase 2 trial of bezisterim in newly diagnosed patients to start soon appeared first on Parkinson's News Today.

https://parkinsonsnewstoday.com/news/phase-2-trial-bezisterim-newly-diagnosed-parkinsons-advances/

Parkinsons News Today

Categories

0 Comments

Submit a Comment

Parkinsons, Odd behaviour and Medications

Parkinsons, Odd behaviour and Medications

Do you have a friend or loved one with Parkinsons ? You reckon that would be bad enough ? Is their behaviour a bit (or a lot or even dangerously) out of character? It may be the drugs they are taking and not their real self or the disease!Please read ALL of this post...

Introduction and Excuse me!

Introduction and Excuse me!

Pardon me, while I get this social media enterprise working. It has taken me 12 months to get this far with this editorial labyrinth. My former pre Parkinson’s self would have had this whipped up in a week or two, reality changes ability, however I won’t let it kill...

They Call me Shuffles

They Call me Shuffles

    A diagnosis with Parkinson's changes a lot of things: Motor function, non-motor functions, but maybe even more powerful is the changes in social interactions. I personally don't mind being called "Shuffles" now, I did at first (8 or so years ago I think), I...